00:20:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-05-20 Årsstämma
2025-05-14 Kvartalsrapport 2025-Q1
2025-02-25 Bokslutskommuniké 2024
2024-10-31 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-06-12 X-dag ordinarie utdelning DIABIO 0.00 SEK
2024-06-11 Årsstämma
2024-05-31 Kvartalsrapport 2024-Q1
2024-02-28 Bokslutskommuniké 2023
2023-10-31 Kvartalsrapport 2023-Q3
2023-09-22 Extra Bolagsstämma 2023
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-12 X-dag ordinarie utdelning DIABIO 0.00 SEK
2023-05-11 Årsstämma
2023-05-11 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-23 Extra Bolagsstämma 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-12 X-dag ordinarie utdelning DIABIO 0.00 SEK
2022-05-11 Årsstämma
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Diagonal Bio är verksamt inom bioteknik. Bolaget utvecklar en plattform under namnet Panviral för att detektera och diagnostisera små sektioner av patogengenom, som exempelvis virus, bakterier och svampar. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Sverige med huvudkontor i Lund.
2024-08-21 15:10:00

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has secured an order from the Technical University of Denmark ("DTU") valued at just over 210,000 SEK for fish farms' health project HURTIGFISK. The order includes supply of Diagonal Bios diagnostic instrument LAMPlify®, consumables and consulting services. The project aims to revolutionise monitoring of fish farm diseases, by point-of-care diagnostics.

The Technical University of Denmark (DTU) and Copenhagen University (KU) has received funding for a fish health project, HURTIGFISK, a project which is a part of KU's efforts to advance fish diagnostics. Diagonal Bio will be a subcontractor to the project as the order includes delivery of the LAMPlify® instrument, along with consumables and comprehensive consulting services. The HURTIGFISK project is scheduled to begin on November 1st and the revenues from the received order will partly be recognised starting from the fourth quarter.

The HURTIGFISK project aims to develop assays against fish pathogens that can drastically reduce the incidence of diseases in fish farming through rapid and accurate testing and diagnosis. By utilising the technology eLAMP embedded in LAMPlify®, fish producers will explore the possibility to conduct disease diagnoses in fishes within 15 minutes. This capability is expected to reduce the number of disease-related fish deaths by 50%, significantly enhancing both animal welfare and productivity.

"By incorporating eLAMP technology into our HURTIGFISK project, we can develop new assays and hopefully achieve a level of precision, speed and diagnosis that has not been possible before. This will make a substantial difference to both animal welfare and productivity within the fish industry" - Helene Larsen, Head of Centre for Diagnostics at DTU Health Tech

"DTU has been a valued partner of Diagonal Bio since the early stages, and collaborating with them on a project of this scale and significance proves the trust and strength of our partnership. We are extremely proud to be a subcontractor to the project HURTIGFISK and look forward to contributing with our expertise and technology." - Karin Wehlin, CEO of Diagonal Bio

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on August 21, 2024, at 15:10 CET.